The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Breakthrough Technology Meets High-Touch Patient Care
Measuring dark adaptation speed with the AdaptDx Pro® can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.
Latest News & Upcoming EventsView More
Jessica Marshall, OD, of Holmdel, New Jersey, takes the discussion about AMD out of the exam room and into everyday conversation with "Macula Mondays."
During the COVID slowdown, researchers seem to have sped up publishing breakthrough research on age-related macular degeneration. Much of this can be applied to real-life optometric practice.
Dr. Timothy Earley shares tips on how to talk to patients about smoking cessation, the biggest modifiable risk factor for AMD, and how to motivate them to quit.